Case scenario

Trang started antiretroviral therapy in 2010. Initially she was prescribed tenofovir disoproxil fumarate + emtricitabine (combination tablet) plus dolutegravir. A few years ago her doctor changed her to Biktarvy (tenofovir alafenamide + emtricitabine + bictegravir) to reduce the pill burden. She has always been virologically suppressed and takes no other medicines. Today she presents you with a new prescription for Dovato (dolutegravir + lamivudine). She explains that she has been doing some reading with her doctor and they found switching to dual therapy is approved as a safe option for suppressed patients with no prior resistance.

Learning objectives

After successful completion of this CPD activity, pharmacists should be able to:

  • Discuss comorbidity considerations that need to be made when choosing anti­retroviral therapy for HIV
  • Describe key factors for consideration when switching antiretroviral therapy
  • Explain the pharmacist’s role in supporting people living with HIV who also have comorbidities or coinfections.

Competency (2016) Standards addressed:  1.1, 1.4, 1.5, 2.2, 3.1, 3.5.

Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

View and submit answers for the EXTENDED LEARNING ACTIVITY here.

Introduction

Human immunodeficiency virus (HIV) treatment and prevention strategies have come a long way over the past few decades. With the advent of highly active comb

THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.

CPD LOGIN
Click here to become a member

RELATED ARTICLESMORE FROM AUTHOR